Physician profile
Farhad Kapadia
NPI 1942428362
$3,027.92
in general payments reported to CMS, 2019-2025
9 companies · $807 in 2025
The $807 reported for 2025 was more than what 82% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $50.96 · 2021: $214 · 2022: $543 · 2023: $749 · 2024: $465 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883 · Entertainment: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.08 |
| Entertainment | $137.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $773.90 | 2022-2025 | Infuse, Envista Mx60 Iol, Envista Aspire Iol |
| Sun Pharmaceutical Industries INC. | $531.59 | 2021-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $418.48 | 2021-2025 | Acuvue |
| Coopervision INC. | $310.52 | 2022-2025 | Clariti Contact Lens, Misight Contact Lens |
| Glaukos Corporation | $282.71 | 2023-2025 | Photrexa Viscous and Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $250.31 | 2019-2020 | |
| Dompe US, INC. | $197.72 | 2022-2024 | Oxervate |
| Optos, INC. | $137.51 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Harrow Eye, LLC | $125.18 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Kapadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.